JS014 + toripalimab

JS014 + toripalimab is an investigational combination therapy being studied for the treatment of advanced or unresectable hepatocellular carcinoma (HCC), particularly in patients who are not candidates for surgical resection. The regimen combines two monoclonal antibodies: - **JS014** (details on its specific target and mechanism are not publicly available as of June 2025, but it is under clinical investigation in oncology). - **Toripalimab**, a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells. By blocking PD-1 interaction with its ligands PD-L1 and PD-L2, toripalimab enhances T-cell mediated immune responses against tumor cells. The combination is being evaluated alongside transarterial chemoembolization (TACE), a locoregional therapy commonly used in liver cancer. The goal of this combination is to improve tumor response rates, delay disease progression, and prolong survival compared to standard treatments alone[1][2][3].

Other names

JS014 + toripalimab